Fluconazole Preparation Market Report 2024

This Fluconazole Preparation market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The fluconazole preparation market size has grown rapidly in recent years. It will grow from $41.75 billion in 2023 to $47.36 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth during the historic period can be attributed to a rise in fungal infections, greater awareness of antifungal treatments, the expansion of the generic drug market, an increasing population of immunocompromised individuals, and more research funding.

The fluconazole preparation market size is expected to see rapid growth in the next few years. It will grow to $78.69 billion in 2028 at a compound annual growth rate (CAGR) of 13.5%. The growth during the forecast period can be attributed to the expansion of online pharmacies, a greater emphasis on preventive healthcare, government support and initiatives, a growing aging population, and the expansion of the generic drug market. Major trends include innovations in nanotechnology, advancements in drug delivery systems, progress in personalized medicine, integration of digital health, and the rise of telepharmacy services.

The rising occurrence of fungal infections is projected to drive the growth of the fluconazole preparation market in the future. Fungal infections are diseases caused by fungi that can impact various areas of the body, including the skin, nails, and lungs. The increase in these infections is attributed to factors such as a growing population of immunocompromised individuals, climate change, and the extensive use of antibiotics. Fluconazole preparations combat fungal infections by inhibiting the production of ergosterol, an essential component of fungal cell membranes, which stops fungal growth and effectively eradicates the infection from the body. For example, in July 2024, The Lancet Infectious Diseases, a peer-reviewed medical journal based in the UK, reported approximately 6.5 million new cases of invasive fungal infections annually, resulting in 3.8 million deaths, with about 2.5 million (68%, ranging from 35% to 90%) directly linked to these infections. Consequently, the increasing rates of fungal infections are fueling the growth of the fluconazole preparation market.

The growth of the fluconazole preparation market is also supported by rising healthcare expenditure. Healthcare expenditure encompasses the total amount spent on medical services, products, and treatments over a given period. The increase in healthcare expenditure is driven by higher medical service costs, technological advancements, and an aging population requiring more care. This rising expenditure facilitates the research, development, and production of fluconazole, ensuring its availability for treating fungal infections. For example, in January 2024, the National Institutes of Health reported a 4.1% increase in U.S. healthcare expenditure in 2022, reaching $4.5 trillion, compared to a 3.2% rise in 2021. Consequently, the growth in healthcare expenditure is contributing to the expansion of the fluconazole preparation market.

Key players in the fluconazole preparation market are concentrating on innovative approaches, such as the development of generic drugs, to provide more cost-effective alternatives to brand-name medications. Generic drug development involves creating and manufacturing bioequivalent versions of branded drugs, offering the same therapeutic benefits at a reduced cost once the original patent expires. For instance, in October 2023, Lupin Limited, an India-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluconazole Tablets USP in 50 mg, 100 mg, 150 mg, and 200 mg strengths. These generic tablets, equivalent to Pfizer's Diflucan, will be produced at Lupin’s Pithampur facility and are aimed at capturing a share of the U.S. market, which had estimated annual sales of USD 43 million. This approval highlights Lupin’s strategy to enhance its presence in the U.S. pharmaceutical market through its manufacturing and research capabilities.

Major companies operating in the fluconazole preparation market are Pfizer Inc., Bayer AG, Novartis AG, Fresenius Kabi, Viatris Inc., Teva Pharmaceutical Industries Ltd., Yangtze River Pharmaceutical Group Co. Ltd., B. Braun SE, Sun Pharmaceutical Industries Ltd., Strides Pharma Science Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Apotex Inc., Sichuan Kelun Pharmaceutical Co. Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Zydus Group, Hetero Drugs Ltd., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Medochemie Ltd, Taj Pharmaceuticals Ltd.

North America was the largest region in the fluconazole preparation market in 2023. The regions covered in the fluconazole preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fluconazole preparation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fluconazole preparation involves formulating the antifungal medication fluconazole, which is available in tablet, oral suspension, or injectable forms. This medication treats fungal infections by inhibiting fungal growth and is prepared according to strict pharmaceutical standards to ensure its efficacy and safety.

The primary types of fluconazole preparations are capsules, tablets, eye drops, and other forms. A fluconazole capsule is a solid dosage form encased in a gelatin shell, designed to deliver a precise oral dose of the medication for treating fungal infections. These preparations are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in various settings such as hospitals and clinics.

The fluconazole preparation market research report is one of a series of new reports that provides fluconazole preparation market statistics, including fluconazole preparation industry global market size, regional shares, competitors with a fluconazole preparation market share, detailed fluconazole preparation market segments, market trends and opportunities, and any further data you may need to thrive in the fluconazole preparation industry. This fluconazole preparation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluconazole preparation market consists of sales of oral suspensions, injections, topical creams, ointments, intravenous solutions, and powders for reconstitution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.